Company overview
Autolomous develops critical manufacturing management systems and digital platforms for cell and gene therapy (CGT) production. Their AutoloMATE solution streamlines data management and automates workflows to help manufacturers reduce costs, scale operations, and deliver therapies to more patients. The company partners with CDMOs and advanced therapy manufacturers to implement digitized supply chain ecosystems and gain operational efficiencies.
Cell & Gene Therapy Manufacturing Software is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing, Lab Equipment & Instruments partner serving United States & Americas. Core focus areas include cell and gene therapy manufacturing, cgt manufacturing software, advanced therapy data management, manufacturing automation, cdmo solutions.
Industry categories: CDMO & Manufacturing, Lab Equipment & Instruments. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Cell & Gene Therapy Manufacturing Software include Cdmo, Software, Automation — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://autolomous.com
- Categories
- CDMO & Manufacturing, Lab Equipment & Instruments
- Markets served
- United States & Americas
- Keywords
- cell and gene therapy manufacturing, cgt manufacturing software, advanced therapy data management, manufacturing automation, cdmo solutions
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What specific solutions does Autolomous offer for CGT manufacturing?
- Autolomous provides AutoloMATE, a fully integrated data management platform designed specifically for advanced therapy manufacturing. The platform enables manufacturers to streamline workflows, automate processes, and gain new insights through digitized supply chain ecosystems.
- Who are Autolomous's typical customers?
- Autolomous serves cell and gene therapy manufacturers, including contract development and manufacturing organizations (CDMOs). The company has demonstrated partnerships with organizations like the Center for Breakthrough Medicines and collaborates with industry bodies such as the Cell and Gene Therapy Catapult.
- How does Autolomous help reduce manufacturing costs?
- By providing critical manufacturing management systems that automate and streamline CGT production workflows, Autolomous enables manufacturers to reduce operational costs and scale their operations more efficiently, ultimately allowing them to deliver therapies to more patients.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
